Pharmaceutical Formulation Facilities as Sources of Opioids and Other Pharmaceuticals to Wastewater Treatment Plant Effluents

Facilities involved in the manufacture of pharmaceutical products are an under-investigated source of pharmaceuticals to the environment. Between 2004 and 2009, 35 to 38 effluent samples were collected from each of three wastewater treatment plants (WWTPs) in New York and analyzed for seven pharmaceuticals including opioids and muscle relaxants. Two WWTPs (NY2 and NY3) receive substantial flows (>20% of plant flow) from pharmaceutical formulation facilities (PFF) and one (NY1) receives no PFF flow. Samples of effluents from 23 WWTPs across the United States were analyzed once for these pharmaceuticals as part of a national survey. Maximum pharmaceutical effluent concentrations for the national survey and NY1 effluent samples were generally <1 μg/L. Four pharmaceuticals (methadone, oxycodone, butalbital, and metaxalone) in samples of NY3 effluent had median concentrations ranging from 3.4 to >400 μg/L. Maximum concentrations of oxycodone (1700 μg/L) and metaxalone (3800 μg/L) in samples from NY3 effluent exceeded 1000 μg/L. Three pharmaceuticals (butalbital, carisoprodol, and oxycodone) in samples of NY2 effluent had median concentrations ranging from 2 to 11 μg/L. These findings suggest that current manufacturing practices at these PFFs can result in pharmaceuticals concentrations from 10 to 1000 times higher than those typically found in WWTP effluents.

[1]  S. Costanzo,et al.  The occurrence of antibiotics in an urban watershed: from wastewater to drinking water. , 2009, The Science of the total environment.

[2]  K. Thomasb,et al.  Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom , 2004 .

[3]  Kevin V Thomas,et al.  Determination of pharmaceutical compounds in hospital effluents and their contribution to wastewater treatment works. , 2009, Environment international.

[4]  Brett J. Vanderford,et al.  Analysis of pharmaceuticals in water by isotope dilution liquid chromatography/tandem mass spectrometry. , 2006, Environmental science & technology.

[5]  D. Barceló,et al.  Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. , 2010, Environment international.

[6]  Mats Tysklind,et al.  Contamination of surface, ground, and drinking water from pharmaceutical production , 2009, Environmental toxicology and chemistry.

[7]  T. Knepper,et al.  Occurrence and fate of barbiturates in the aquatic environment. , 2006, Environmental science & technology.

[8]  Cheng-Fang Lin,et al.  Pharmaceutical contamination in residential, industrial, and agricultural waste streams: risk to aqueous environments in Taiwan. , 2008, Chemosphere.

[9]  D. Calamari,et al.  Effects of a complex mixture of therapeutic drugs at environmental levels on human embryonic cells. , 2006, Environmental science & technology.

[10]  J. Lazorchak,et al.  Risks to aquatic organisms posed by human pharmaceutical use. , 2008, The Science of the total environment.

[11]  R. Velagaleti,et al.  Impact of current good manufacturing practices and emission regulations and guidances on the discharge of pharmaceutical chemicals into the environment from manufacturing, use, and disposal. , 2002, Environmental health perspectives.

[12]  D. Kolpin,et al.  Method Description, Quality Assurance, Environmental Data, and other Information for Analysis of Pharmaceuticals in Wastewater-Treatment-Plant Effluents, Streamwater, and Reservoirs, 2004-2009 , 2010 .

[13]  Thomas Heberer,et al.  Contribution of effluents from hospitals and private households to the total loads of diclofenac and carbamazepine in municipal sewage effluents--modeling versus measurements. , 2005, Journal of hazardous materials.

[14]  Peter Shanahan,et al.  Screening analysis of human pharmaceutical compounds in U.S. surface waters. , 2004, Environmental science & technology.

[15]  D. Kolpin,et al.  Transport of chemical and microbial compounds from known wastewater discharges: potential for use as indicators of human fecal contamination. , 2005, Environmental science & technology.

[16]  B. Paull,et al.  Using environmental analytical data to estimate levels of community consumption of illicit drugs and abused pharmaceuticals. , 2007, Journal of environmental monitoring : JEM.

[17]  Jaeweon Cho,et al.  Occurrence and removal of pharmaceuticals and endocrine disruptors in South Korean surface, drinking, and waste waters. , 2007, Water research.

[18]  Michael P. Schroeder,et al.  Methods of analysis by the U.S. Geological Survey National Water Quality Laboratory--Determination of wastewater compounds by polystyrene-divinylbenzene solid-phase extraction and capillary-column gas chromatography/mass spectrometry , 2002 .

[19]  M. Stenstrom,et al.  Human Pharmaceuticals, Antioxidants, and Plasticizers in Wastewater Treatment Plant and Water Reclamation Plant Effluents , 2007, Water environment research : a research publication of the Water Environment Federation.

[20]  H Kroiss,et al.  Removal of selected pharmaceuticals, fragrances and endocrine disrupting compounds in a membrane bioreactor and conventional wastewater treatment plants. , 2005, Water research.

[21]  B. Quinn,et al.  An investigation into the acute and chronic toxicity of eleven pharmaceuticals (and their solvents) found in wastewater effluent on the cnidarian, Hydra attenuata. , 2008, The Science of the total environment.

[22]  M. Crane,et al.  Chronic aquatic environmental risks from exposure to human pharmaceuticals. , 2006, The Science of the total environment.

[23]  Alejandro J. Ramirez,et al.  Enantiospecific sublethal effects of the antidepressant fluoxetine to a model aquatic vertebrate and invertebrate. , 2007, Chemosphere.

[24]  M. I C H A E,et al.  Pharmaceuticals, Hormones, and Other Organic Wastewater Contaminants in U.S. Streams, 1999-2000: A National Reconnaissance , 2002 .

[25]  D. Kolpin,et al.  Antidepressant pharmaceuticals in two U.S. effluent-impacted streams: occurrence and fate in water and sediment, and selective uptake in fish neural tissue. , 2010, Environmental science & technology.

[26]  Jan S Peterson,et al.  U.s. Code of Federal Regulations. , 2003, Journal of cataract and refractive surgery.

[27]  Lorien J. Fono,et al.  Emerging compounds: A concern for water and wastewater utilities , 2008 .

[28]  D. Larsson,et al.  Effluent from drug manufactures contains extremely high levels of pharmaceuticals. , 2007, Journal of hazardous materials.

[29]  Guido Fink,et al.  Simultaneous determination of psychoactive drugs and their metabolites in aqueous matrices by liquid chromatography mass Spectrometry. , 2006, Environmental science & technology.

[30]  M. Slattery,et al.  Waterborne and sediment toxicity of fluoxetine to select organisms. , 2003, Chemosphere.

[31]  V. Decottignies,et al.  Analysis of drugs and personal care products in French source and drinking waters: the analytical challenge and examples of application. , 2005, Water science and technology : a journal of the International Association on Water Pollution Research.

[32]  G. Nentwig.  Effects of Pharmaceuticals on Aquatic Invertebrates. Part II: The Antidepressant Drug Fluoxetine , 2007, Archives of environmental contamination and toxicology.

[33]  Ralf Schulz,et al.  Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance? , 2010, Environmental science & technology.

[34]  S. Klaine,et al.  Behavioral and biochemical responses of hybrid striped bass during and after fluoxetine exposure. , 2008, Aquatic toxicology.